Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SMND-309 is a metabolite of salvianolic acid B. It also shows neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats.
产品描述 | SMND-309 is a metabolite of salvianolic acid B. It also shows neuroprotective effects in cultured neurons and in permanent middle cerebral artery occlusion rats. |
体内活性 | SMND-309 treatment decreases the liver damage and the liver fibrosis grade. SMND-309 also reduces the elevation in the malondialdehyde level and restored the decrease in superoxide dismutase and glutathione peroxidase activities. SMND-309 treatment powerfully down-regulated the expression of connective tissue growth factor (CTGF) in serum and liver. SMND-309 (2.5-10 mg/kg; oral intragastric; once a day; for 4 weeks; male Sprague-Dawley rats) treatment ameliorates liver function and decreases the elevation of serum hyaluronic acid, laminin, procollagen type III levels and hydroxyproline content in liver tissue [1]. |
分子量 | 358.302 |
分子式 | C18H14O8 |
CAS No. | 1065559-56-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.7 mg/mL (10.33 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.7909 mL | 13.9547 mL | 27.9094 mL | 69.7735 mL |
5 mM | 0.5582 mL | 2.7909 mL | 5.5819 mL | 13.9547 mL | |
10 mM | 0.2791 mL | 1.3955 mL | 2.7909 mL | 6.9774 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SMND-309 1065559-56-9 Others SMND 309 SMND309 Inhibitor inhibitor inhibit